Shane Shapera

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Joshua J. Solomon, Sonye K. Danoff, Felix Woodhead et al. · The Lancet Respiratory Medicine · 2022 · 208 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

Nathan Hambly, Mohammed A. Farooqi, Anna Dvorkin‐Gheva et al. · European Respiratory Journal · 2022 · 185 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

Toby M. Maher, Paul Ford, Kevin M. Brown et al. · JAMA · 2023 · 127 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis

Jolene H. Fisher, Darragh O’Connor, Alana M. Flexman et al. · American Journal of Respiratory and Critical Care Medicine · 2016 · 121 citations

Computing, Health Informatics, Pharmacotherapy +16